retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Reports retatrutide triple agonist glp-1 gip

That leaves open questions about long-term and real-world risks

Most healthcare providersand most patientsreasonably decide that stopping before conception is the more conservative, prudent approach until we have better information

00:18:32 Don Weinberger: It is

A degraded peptide from improper storage might produce inconsistent appetite suppression and, potentially, inconsistent digestive side effects from dose to dose

Because of this, the Diabetes Prevention Program study has shown that for people with prediabetes or metabolic risk , metformin can gently support weight management and delay diabetes development over the long term

recently published a study on 2562 case subjects that showed an increased risk of all thyroid cancers (adjusted HR 1.58, 95% CI 1.271.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.043.5) after 13 years of GLP-1 RA use [78]